Across TCGA pan-cancer cohorts, FBXL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXL3 data layer compared with 22 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FBXL3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FBXL3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.
HNSC, LUAD, and CCRCC are the cancer types where FBXL3 mass-spec protein most reproducibly stratifies survival.